Surgery Partners (SGRY) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Dave Doherty - EVP & CFOEric Evans - CEOBenjamin Rossi - Equity Research AssociateAndrew Mott - Director, Team Leader and Co-Head of Private BankA.J. Rice - Managing DirectorWhit Mayo - Senior Managing DirectorBen Hendrix - Vice President Conference Call Participants Brian Tanquilut - Equity Research Analyst - Healthcare ServicesJoanna Gajuk - Equity Research AnalystSarah James - Managing Director & Equity Analyst - ...

Heart of Healthcare Under Pressure: 1 in 3 Nurses Near Retirement as Continued Volatility PersistsDALLAS, May 12, 2025 (GLOBE NEWSWIRE) -- While 75% of nurses report being satisfied with their career choice, many still face significant strain due to burnout, mental health challenges, and staffing issues, according to a new survey by AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations. More than half of nurses (58%) report feeling burnout most days, and only 39% pl ...

Doximity (DOCS) is scheduled to release fourth-quarter fiscal 2025 results on May 15, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 36.36%. DOCS delivered a trailing four-quarter average earnings surprise of 26.00%.DOCS Q4 EstimatesCurrently, the consensus estimate for revenues is pegged at $133.8 million. The consensus mark for earnings is pinned at 27 cents per share.Factors to NoteDoximity’s fourth-quarter fiscal 2025 performance is expected ...

Core Viewpoint - Aclarion, Inc. has announced the Texas Back Institute as a new site for its pivotal CLARITY trial, which aims to demonstrate the clinical and economic value of its Nociscan technology in spine surgery [1][4]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][6]. - The company's Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and nonpainful lumbar discs [4][7]. CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain [3]. - The trial will randomize patients in a 1:1 ratio between surgeons blinded to Nociscan results and those unblinded, guiding surgical treatment decisions [3]. - The primary endpoint is the change in back pain measured on a 100mm Visual Analog Scale (VAS) at 12 months compared to baseline [3]. Texas Back Institute's Role - Texas Back Institute is recognized for its excellence in research and has participated in various studies related to spine treatments [2][4]. - The institute's involvement in the CLARITY trial is expected to enhance the study's credibility and align with its patient population [2][4]. Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge it presents [4]. - Aclarion's Nociscan aims to improve surgical outcomes by providing critical insights into the sources of low back pain through advanced diagnostic techniques [4][7].

Industry Overview - The healthcare industry has faced challenges in early 2025, including concerns over potential cuts to Medicare and Medicaid, as well as the impact of tariffs on supplies [1] - Despite these challenges, healthcare stocks have performed relatively well, with the Health Care Select Sector SPDR Fund (XLV) down less than 2% year-to-date, compared to the S&P 500's decline of nearly 3% [1] Company Analysis: Centene - Centene Corp. (CNC) has shown solid membership and revenue growth, primarily driven by its Medicaid services, which have helped it withstand market volatility [3][4] - For Q1 2025, Centene reported a 29% year-over-year increase in Marketplace membership and a 22% increase in Medicare membership, contributing to a 28% improvement in adjusted diluted earnings per share (EPS) and a 17% growth in premium and service revenue [4] - The company has reiterated its full-year guidance, indicating optimism for future performance [4] Company Analysis: Tenet Healthcare - Tenet Healthcare Corp. (THC) has received positive analyst ratings, with 13 Buy ratings and four Holds, following a strong Q1 2025 earnings report that exceeded EPS estimates by $1.25 per share, reflecting a year-over-year improvement of over 35% [6][7] - The company plans to invest $250 million annually in its Ambulatory segment and has opened six new centers in Q1 2025, which are expected to drive continued growth [8] - Tenet's share repurchase program and efforts to improve its balance sheet are anticipated to enhance shareholder value [8] Company Analysis: Encompass Health - Encompass Health Corp. (EHC) reported better-than-expected earnings, leading to increased price targets from analysts [10] - The company's shares have risen over 25% year-to-date, with expectations of 10% projected earnings growth in the near term [11]

American Healthcare REIT (AHR) Q1 2025 Earnings Call May 09, 2025 01:00 PM ET Company Participants Alan Peterson - Vice President of Investor Relations & FinanceDanny Prosky - President & CEOGabe Willhite - COOStefan Oh - Chief Investment OfficerBrian Peay - Chief Financial OfficerFarrell Granath - Equity Research AssociateMichael Carroll - Managing Director & Head of US Real Estate ResearchRonald Kamdem - Managing Director & Head of US REITs and CRE ResearchJoe Dickstein - VP - Equity Research Conference C ...

Financial Data and Key Metrics Changes - The company reported normalized funds from operations (NFFO) of $0.38 per fully diluted share, representing an increase of over 26% compared to Q1 2024 [25] - The net debt to annualized adjusted EBITDA stood at 4.5 times at the end of the quarter [11][28] - Full year 2025 same store NOI growth targets were increased to a range of 9% to 13% from a prior range of 7% to 10% [26] Business Line Data and Key Metrics Changes - The company achieved 15.1% same store NOI growth year over year in Q1 2025, driven by the operating portfolio, particularly the Trilogy and SHOP segments [8][12] - Trilogy reported a year-over-year same store NOI growth of 19.8%, while SHOP experienced a growth of 30.7% in Q1 2025 [12] - The Trilogy segment's same store NOI growth guidance was revised upward to a range of 12% to 16% from a previous range of 10% to 12% [27] Market Data and Key Metrics Changes - The company noted a sharp uptick in move-ins since the end of Q1, indicating strong demand in the assisted living market [9][70] - The company is experiencing favorable fundamentals in the senior housing industry, benefiting from a multi-year tailwind [9] Company Strategy and Development Direction - The company is focused on delivering high-quality care and improving health outcomes, which is central to its operational strategy [6][7] - The investments team is actively identifying new growth opportunities and has a pipeline of over $300 million in potential acquisitions [20] - The company is prioritizing partnerships with market leaders and expanding its operator base to enhance growth opportunities [10][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth across the operating portfolio, particularly as demand for assisted living care increases in warmer months [9] - The company anticipates that the senior housing industry will continue to benefit from favorable demographics and demand trends [9][15] - Management highlighted the importance of quality care and operational efficiency as key drivers for future success [95] Other Important Information - The company successfully closed a lease buyout of a Trilogy campus for approximately $16.1 million and acquired a $65 million SHOP community [19] - The company raised approximately $48 million through its ATM program at an average price of $30.22 per share [25] Q&A Session Summary Question: Can you provide more detail on the investment pipeline and expected close? - Management indicated that the pipeline is robust, with transactions expected to close mostly in the fourth quarter, depending on regulatory approvals [33][34] Question: How is the company thinking about its MOB and triple net portfolio? - The company has been selling off non-core MOB assets, focusing on higher risk-adjusted returns in long-term care [38][41] Question: Can you share details on the investment pipeline's competitiveness and economics? - The pipeline consists of over $300 million, primarily newer buildings, with attractive pricing and yields [46][47] Question: What is the expected impact of tariffs on the business? - Management believes the company is well-positioned to handle potential impacts from tariffs, with a focus on maintaining pricing power [76][79] Question: Can you elaborate on the recent uptick in move-ins and pricing strategies? - The company has seen a significant increase in move-ins, with a focus on reducing concessions and implementing dynamic pricing strategies [70][72] Question: How does Trilogy support SHOP operational efficiency? - Trilogy provides resources such as revenue management and training to regional operators, enhancing overall operational efficiency [95][96]

First Quarter 2025 Supplemental Disclaimers Forward-Looking Statements Certain statements contained in this supplemental, filed in conjunction with the First Quarter 2025 Earnings Press Release, including statements relating to American Healthcare REIT, Inc.'s (the "Company") expectations regarding its performance, interest expense savings, balance sheet, net income or loss per diluted share, NAREIT FFO per diluted share, NFFO per diluted share, NOI growth, total portfolio Same-Store NOI growth, segment-lev ...

Analysts on Wall Street project that Steris (STE) will announce quarterly earnings of $2.58 per share in its forthcoming report, representing an increase of 7.1% year over year. Revenues are projected to reach $1.48 billion, increasing 4.2% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...

Core Viewpoint - SRx Health Solutions, Inc. plans to establish a subsidiary to borrow cryptocurrencies like Solana and Bitcoin against its Halo assets, aiming to enhance financial flexibility for its business operations [1][2]. Group 1: Company Strategy - The proposed subsidiary will allow SRx to leverage its Halo profits in exchange for cryptocurrency, thereby limiting dilution for common shareholders while providing operational financial flexibility [2]. - The capital raised through this initiative will be directed towards marketing and sales budgets for the Halo brand, indicating a strategic focus on growth and market presence [2]. Group 2: Company Overview - SRx Health Solutions, Inc. is a Canadian healthcare services provider operating in the specialty healthcare industry, with a network that spans all ten Canadian provinces [3]. - The company emphasizes a patient-centric approach, combining industry knowledge and technology to deliver customized healthcare solutions that aim to improve wellness for Canadians [3].